Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06386315
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent Indolent Non-Hodgkin Lymphoma
- Refractory Indolent B-Cell Non-Hodgkin Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Computed Tomography — PROCEDUREUndergo CT or PET/CT
- Endoscopic Procedure — PROCEDUREUndergo endoscopy
- Involved-site Radiation Therapy (3 Fractions) — RADIATIONUndergo ISRT in 3 fractions
- Involved-site Radiation Therapy (12 Fractions) — RADIATIONUndergo ISRT in 12 fractions
- Positron Emission Tomography — PROCEDUREUndergo PET/CT
- Questionnaire Administration — OTHERAncillary studies
Study Details
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
Key Dates
- Start date
- May 15, 2024
- Status verified
- Apr 2026
- Primary completion
- May 30, 2027
- Completion
- May 30, 2027
Study Design
- Enrollment
- 112 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ARM 1 (reduced dose ISRT)Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
- Active Comparator: ARM 2 (SOC ISRT)Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
Primary Outcome Measure
Incidence of grade 2 or higher acute adverse events (AEs) [ Time Frame: Up to 14 days after radiation treatment ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | William G. Rule, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | Brad S. Hoppe, MD, MPH (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System in Albert Lea | Albert Lea | Minnesota | 56007 | John Yeakel, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System - Mankato | Mankato | Minnesota | 56001 | Jason T. Hayes, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Scott C. Lester, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System-Eau Claire Clinic | Eau Claire | Wisconsin | 54701 | Now Bahar Alam, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | 54601 | Abigail L. Stockham, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Scottsdale, AZ
Related Studies
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLPHASE1/PHASE2 · Recruiting · BioInvent International AB · Atlanta, Georgia
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesPHASE1 · Recruiting · Sumithira Vasu · Columbus, Ohio
- SynKIR-310 for Relapsed/Refractory B-NHLPHASE1 · Recruiting · Verismo Therapeutics · Denver, Colorado
- ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaPHASE1/PHASE2 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington